Nomura Holdings’s Kyntra Bio KYNB Stock Holding History

Nomura Holdings’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,584	Closed	-$125K	–	1692
2024 Q2	$125K	Buy	+5,584	New	+$173K	﹤0.01%	1674

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Nomura Holdings's KYNB Position: Q3 2021 in Review

Nomura Holdings sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 590 shares — an estimated $394K sold.

Nomura Holdings first reported a position in KYNB in Q1 2020 and held it in 2 quarters. The position peaked at $589K in Q1 2020. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

Nomura Holdings reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
Nomura Holdings sold 590 Kyntra Bio shares in Q3 2021, an estimated $394K.
Nomura Holdings first reported a position in Kyntra Bio in Q1 2020 and held it in 2 quarters.
Nomura Holdings's Kyntra Bio position peaked at $589K in Q1 2020.
164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Nomura Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.